tailieunhanh - Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) – a prospective, randomized, 2-armed phase-II-trial

The incidence of anal cancer is rising in the last decades and more women are affected than men. The prognosis after chemoradiation is very good with complete remission rates of 80–90%. Thus, reducing therapyrelated toxicities and improving quality of life are of high importance. | Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy DILANA a prospective randomized 2-armed phase-II-trial

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN